The CFH gene helps keep part of your immune system, called complement, from attacking your own healthy tissues. If it does not work properly, complement activity can become too strong and may damage the retina in the eye, the kidneys, or small blood vessels. This gene plays an important role in protecting the macula, so some CFH variants are linked to a higher chance of age-related macular degeneration. Certain rare, more disruptive variants can also cause inherited kidney conditions such as atypical hemolytic uremic syndrome and C3 glomerulopathy.
What is a gene?
Genes are sections of DNA that carry instructions your cells use to make molecules or regulate processes in the body. Some genes hold the directions for producing proteins, which are the working parts of cells. Other genes mainly guide when certain processes happen, where they occur, and how strongly they operate. As a whole, genes affect how the body develops and works, and they can also influence how you respond to food, stress, or medications. To go into this topic in more detail, you can find more in the LearnHub.
Overview
CFHGene function
What if the gene works
Your cells use the CFH gene to make factor H, a protein that helps control complement, an immune defense system that fights germs. This helps protect healthy tissues from unintended inflammation and damage.
Risk
What if the gene does not work
Variants in the CFH gene can upset complement control in the immune system. More severe variants may cause atypical hemolytic uremic syndrome or C3 glomerulopathy, while milder variants can raise age-related macular degeneration risk.
Treatment
What does that mean for your treatment
In aHUS, a pathogenic variant in the CFH gene can support use of complement blocking drugs such as eculizumab or ravulizumab and may favor longer treatment because relapse risk can be higher. After kidney transplant, CFH related disease often carries a higher chance of coming back, so preventive complement inhibition may be considered.
Conditions associated with CFH
Gene function
What if the gene works
Your immune system needs careful brakes as well as triggers. The CFH gene helps make a protein that keeps one branch of this system, called complement, from becoming too active. This is a key way the CFH gene helps protect healthy cells from unnecessary immune activity while still supporting normal defense.
The CFH gene helps slow the complement system, a fast acting part of your immune defense. Its protein keeps this pathway from amplifying too freely in blood and on cell surfaces.
This protein attaches to healthy body surfaces by recognizing sialic acids (small sugar markers on cells) and related surface sugars. That helps complement focus less on your own tissues and more on material that does not carry those markers.
CFH binds C3b, an immune tag that can spread complement activity. It also helps factor I, another complement protein, turn C3b into a quieter form so the signal does not keep building.
What is a variant?
A genetic variant is a small difference in the DNA sequence within a gene. These differences are common and help shape normal human diversity, including differences in appearance, metabolism, or the way the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. In some situations, though, a variant can change how a gene works more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the CFH gene can change how factor H works by altering the protein’s shape, stability, or ability to attach to immune targets and cell surfaces, weakening control of the complement system (part of the immune defense). Milder variants may slightly lower factor H levels or binding strength, while more disruptive variants can sharply reduce activity or stop the protein from working normally. This range can affect how early and how strongly related kidney or eye disease appears.
How variants are linked to conditions
Variants in the CFH gene are linked to age-related macular degeneration, and some common changes can raise or lower your chance of developing this eye condition. Pathogenic variants in the CFH gene can also cause atypical hemolytic uremic syndrome and are associated with some C3 glomerulopathy conditions that affect kidney function. In practice, CFH gene variants and macular degeneration risk are discussed differently from rare diagnoses, because common risk variants influence odds rather than guarantee illness.
A variant is not necessarily a diagnosis
Changes in genes are a usual part of human biology and are common across the general population. Most variants do not directly affect health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when several genes and environmental factors also play a role. In some situations, however, a single well-characterized variant in a specific gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
Risk related to the CFH gene depends on the health condition involved. For age-related macular degeneration, older age and smoking can raise risk, while for some rare CFH-related kidney conditions, infections, pregnancy, and certain medicines can help trigger episodes in people who already carry a harmful change.
Inheritance of CFH variants
The way CFH gene variants are inherited depends on the specific CFH related condition. Many CFH variants linked to atypical hemolytic uremic syndrome follow an autosomal dominant pattern, so a parent carrying the variant can pass it to a child with a 50% chance, and some cases happen because of a new variant not inherited from either parent. By contrast, complete factor H deficiency is typically autosomal recessive, which means a child usually inherits one altered copy of the CFH gene from each parent.
What does my CFH result mean for my family?
For CFH, what this means for family members depends on the condition linked to the result. Some CFH changes are passed down in families in a dominant pattern, so close relatives may also carry the change and may want to discuss testing; other CFH-related conditions happen when both copies of the gene are changed, which can mean parents are healthy carriers and siblings may also be affected or be carriers. A doctor or genetic counselor can explain which pattern fits a specific CFH result.
Genetic information
Genetic testing
How you find out about variants
CFH genetic testing for atypical hemolytic uremic syndrome uses blood, saliva, or a cheek swab to read the CFH gene and look for variants. The lab compares your DNA sequence with the usual reference sequence, then reports whether a variant is benign, uncertain, or pathogenic. Results can also help clarify whether relatives may share the same variant.
When should I consider getting a genetic test?
Consider CFH genetic testing if you or close relatives have a rare kidney condition called atypical hemolytic uremic syndrome, or other immune-system related kidney disease, especially when it starts young, keeps coming back, or runs in families. Testing can help show whether CFH is part of the cause and can help with family screening.
A genetic result is only one part of your health story
A genetic finding can give useful insight, yet how much it reveals depends on the condition and on the kind of variant present. Over time, many factors shape how the body works, including lifestyle, environment, age, and medical history. In some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is best considered alongside other parts of care. In other situations, a genetic result may offer a clear answer. In areas such as medication response, genetic results can help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small inherited differences can change how the body absorbs, breaks down, transports, or reacts to a drug, so the same treatment may work better for one person than for another. These differences are common and can influence both how well a medicine helps and how likely someone is to have side effects or need closer monitoring.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences can shape a person’s response to medications. By studying the relationship between genes and drugs, it helps explain why the same treatment may work differently from one person to another. For many medicines, genes influence both how strongly a drug works and how the body processes it. This information can support more informed and individualized treatment decisions. More on this topic is available in the LearnHub.
Drugs influenced by the CFH gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medicine choices, so general questions about treatments or side effects are best discussed with your doctor. CFH has been studied in age-related macular degeneration to see whether gene changes affect response to eye treatments, but this has not become standard care.
History
The CFH gene became a major focus in medical genetics when researchers linked it to age related macular degeneration in the mid 2000s. That discovery helped explain why some families seemed to share a higher chance of this common eye condition. From these first observations, research expanded steadily. Scientists then connected rare variants in the CFH gene to atypical hemolytic uremic syndrome, a condition that can affect the kidneys and blood. These findings also helped clarify a group of older, sometimes confusing diagnoses involving the body’s complement system, part of immune defense. Over time, the CFH gene came to represent a broader shift in medicine, showing how one gene could matter in both common disease risk and rarer inherited conditions.